News & Updates
Filter by Specialty:
Pimavanserin for dementia-related psychosis: to continue or not?
In individuals with dementia-related psychosis (DRP) who had a response to the oral 5-HT2A* inverse agonist and antagonist pimavanserin, an atypical antipsychotic agent, the risk of relapse was lower among those who continued the drug vs those who stopped it, the phase III HARMONY trial suggests.
Pimavanserin for dementia-related psychosis: to continue or not?
01 Oct 2021
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
Treatment with a combination of the recombinant human IgG1 monoclonal antibodies casirivimab and imdevimab reduced hospitalization rates in high-risk patients with mild-to-moderate COVID-19, according to results of a retrospective study.
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
29 Sep 2021
Romosozumab prevents new vertebral fractures in postmenopausal women with osteoporosis
Twelve months of treatment with romosozumab produce marked reductions in new vertebral fractures, especially moderate-to-severe fractures, among postmenopausal women with osteoporosis, according to a study.
Romosozumab prevents new vertebral fractures in postmenopausal women with osteoporosis
29 Sep 2021
Add-on metoprolol of no benefit to high-risk prostate cancer patients
Use of metoprolol among high-risk prostate cancer patients receiving androgen deprivation therapy does not appear to improve oncological outcomes, as shown in a study.
Add-on metoprolol of no benefit to high-risk prostate cancer patients
29 Sep 2021
DPP-4–to–SGLT2 inhibitor switch confers multiple benefits for patients with diabetes, hypertension
In the treatment of patients with type 2 diabetes mellitus and hypertension, switching from a dipeptidyl peptidase-4 (DPP-4) inhibitor to the sodium-glucose cotransporter-2 (SGLT2) inhibitor luseogliflozin appears to have favourable effects on blood pressure (BP), circadian rhythm, and night-time systolic BP (SBP) and pulse rate (PR), according to data from the open-label LUNA trial.
